uniQure's (QURE) "Buy" Rating Reaffirmed at Chardan Capital

Key Points

• Chardan Capital has reaffirmed a "Buy" rating for uniQure (QURE) with a target price of $35.00, indicating a potential upside of nearly 95% from its previous close.
• The stock currently holds a consensus rating of "Buy" among analysts, with the average target price estimated at $37.45.
• In its latest earnings report, uniQure exceeded analysts' expectations with a revenue of $5.26 million and an EPS of ($0.69), better than the anticipated ($0.89).

uniQure (NASDAQ:QURE - Get Free Report)'s stock had its "buy" rating restated by research analysts at Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $35.00 target price on the biotechnology company's stock. Chardan Capital's price objective would suggest a potential upside of 94.99% from the company's previous close.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research report on Wednesday, July 30th. Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price objective on the stock in a research report on Thursday, August 14th. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a research report on Friday. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $37.45.

uniQure Stock Performance

Shares of QURE stock opened at $17.95 on Monday. The stock has a fifty day moving average of $14.98 and a 200 day moving average of $13.81. uniQure has a 52 week low of $4.45 and a 52 week high of $19.18. The firm has a market capitalization of $984.92 million, a price-to-earnings ratio of -4.58 and a beta of 0.13. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. As a group, research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity

In related news, Director Rachelle Suzanne Jacques sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director owned 28,346 shares of the company's stock, valued at approximately $409,599.70. This trade represents a 6.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeannette Potts sold 4,670 shares of uniQure stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the sale, the insider directly owned 115,073 shares in the company, valued at $1,742,205.22. This trade represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,144 shares of company stock worth $322,426. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its position in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 5,538 shares during the last quarter. Mraz Amerine & Associates Inc. bought a new position in shares of uniQure during the 1st quarter valued at approximately $106,000. KLP Kapitalforvaltning AS bought a new position in shares of uniQure during the 2nd quarter valued at approximately $117,000. Teacher Retirement System of Texas bought a new position in shares of uniQure during the 2nd quarter valued at approximately $151,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of uniQure during the 1st quarter valued at approximately $152,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.